-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Short Interest in Molecular Partners AG (NASDAQ:MOLN) Decreases By 9.4%
Short Interest in Molecular Partners AG (NASDAQ:MOLN) Decreases By 9.4%
Molecular Partners AG (NASDAQ:MOLN – Get Rating) saw a significant decline in short interest in the month of August. As of August 31st, there was short interest totalling 26,900 shares, a decline of 9.4% from the August 15th total of 29,700 shares. Based on an average daily trading volume, of 13,200 shares, the days-to-cover ratio is presently 2.0 days.
Institutional Trading of Molecular Partners
An institutional investor recently raised its position in Molecular Partners stock. Federated Hermes Inc. boosted its position in Molecular Partners AG (NASDAQ:MOLN – Get Rating) by 94.2% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 457,037 shares of the company's stock after purchasing an additional 221,743 shares during the quarter. Federated Hermes Inc. owned approximately 1.41% of Molecular Partners worth $9,264,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 2.70% of the company's stock.
Get Molecular Partners alerts:Molecular Partners Stock Performance
MOLN stock opened at $6.39 on Monday. The business has a 50-day moving average price of $6.35 and a 200 day moving average price of $10.52. Molecular Partners has a 1-year low of $5.50 and a 1-year high of $32.04.
Molecular Partners (NASDAQ:MOLN – Get Rating) last released its quarterly earnings data on Thursday, August 25th. The company reported ($0.15) earnings per share for the quarter. The company had revenue of $12.19 million during the quarter. On average, equities analysts anticipate that Molecular Partners will post 3.79 EPS for the current year.Wall Street Analyst Weigh In
Several research firms have recently weighed in on MOLN. Royal Bank of Canada downgraded Molecular Partners from an "outperform" rating to a "sector perform" rating in a research report on Tuesday, August 30th. Credit Suisse Group upgraded Molecular Partners from an "underperform" rating to a "neutral" rating in a research report on Wednesday, May 25th. Finally, SVB Leerink downgraded Molecular Partners from an "outperform" rating to a "market perform" rating and decreased their target price for the stock from $30.00 to $8.00 in a research report on Monday, August 29th.
Molecular Partners Company Profile
(Get Rating)
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus.
See Also
- Get a free copy of the StockNews.com research report on Molecular Partners (MOLN)
- Kroger's is Your One-Stop Consumer Staples Stock
- Adobe Perfects the Art of the Faceplant for Investors
- Tax Credits are the Incentives in the Inflation Reduction Act
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
Molecular Partners AG (NASDAQ:MOLN – Get Rating) saw a significant decline in short interest in the month of August. As of August 31st, there was short interest totalling 26,900 shares, a decline of 9.4% from the August 15th total of 29,700 shares. Based on an average daily trading volume, of 13,200 shares, the days-to-cover ratio is presently 2.0 days.
分子合伙公司(纳斯达克:Moln-Get评级)看到空头股数在8月份出现了显著下降。截至8月31日,空头股数共有26,900股,较8月15日的29,700股下跌9.4%。以日均成交量13,200股计算,目前天数与回补比率为2.0天。
Institutional Trading of Molecular Partners
分子伙伴的制度性交易
An institutional investor recently raised its position in Molecular Partners stock. Federated Hermes Inc. boosted its position in Molecular Partners AG (NASDAQ:MOLN – Get Rating) by 94.2% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 457,037 shares of the company's stock after purchasing an additional 221,743 shares during the quarter. Federated Hermes Inc. owned approximately 1.41% of Molecular Partners worth $9,264,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 2.70% of the company's stock.
一家机构投资者最近提高了对分子合伙公司股票的头寸。联合爱马仕公司(Federated Hermes Inc.)最近提交给美国证券交易委员会的Form 13F文件显示,今年第一季度,该公司将其在分子合伙公司(Moln-Get Rating)的持股比例提高了94.2%。该机构投资者在本季度额外购买了221,743股后,持有该公司457,037股股票。在最近一次报告期结束时,联合爱马仕公司拥有分子伙伴公司约1.41%的股份,价值9,264,000美元。机构投资者和对冲基金持有该公司2.70%的股票。
Molecular Partners Stock Performance
分子合作伙伴股票表现
MOLN stock opened at $6.39 on Monday. The business has a 50-day moving average price of $6.35 and a 200 day moving average price of $10.52. Molecular Partners has a 1-year low of $5.50 and a 1-year high of $32.04.
Moln股价周一开盘报6.39美元。该业务的50日移动均线价格为6.35美元,200日移动均线价格为10.52美元。Molecal Partners的一年低点为5.50美元,一年高位为32.04美元。
Wall Street Analyst Weigh In
华尔街分析师也加入进来
Several research firms have recently weighed in on MOLN. Royal Bank of Canada downgraded Molecular Partners from an "outperform" rating to a "sector perform" rating in a research report on Tuesday, August 30th. Credit Suisse Group upgraded Molecular Partners from an "underperform" rating to a "neutral" rating in a research report on Wednesday, May 25th. Finally, SVB Leerink downgraded Molecular Partners from an "outperform" rating to a "market perform" rating and decreased their target price for the stock from $30.00 to $8.00 in a research report on Monday, August 29th.
几家研究公司最近对莫恩进行了权衡。在8月30日(周二)的一份研究报告中,加拿大皇家银行将分子合伙公司的评级从“跑赢大盘”下调至“行业表现”。瑞士信贷集团在5月25日(周三)的一份研究报告中,将分子合伙公司的评级从表现不佳上调至中性。最后,SVB Leerink在8月29日(周一)的一份研究报告中将分子合伙公司的评级从“跑赢大盘”下调至“市场表现”,并将其股票的目标价从30.00美元下调至8.00美元。
Molecular Partners Company Profile
分子合作伙伴公司简介
(Get Rating)
(获取评级)
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus.
分子伙伴公司是一家临床阶段的生物制药公司,专注于治疗性蛋白质的发现、开发和商业化。它的候选产品包括用于治疗新血管湿性老年性黄斑变性和糖尿病黄斑水肿的候选DARPin药物Abempar,该药物处于第三阶段临床试验;以及针对SARS-CoV-2病毒的多特异性DARPin候选药物MP0420。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Molecular Partners (MOLN)
- Kroger's is Your One-Stop Consumer Staples Stock
- Adobe Perfects the Art of the Faceplant for Investors
- Tax Credits are the Incentives in the Inflation Reduction Act
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 免费获取StockNews.com关于分子伙伴的研究报告(Moln)
- 克罗格百货是你的一站式消费者史泰博股票
- Adobe为投资者完善Facebook工厂的艺术
- 税收抵免是《降低通货膨胀法案》中的激励措施
- 第四季度值得考虑的3家银行
- 股市:红海中的三座强国
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
每日收到分子合作伙伴的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯,接收分子合作伙伴和相关公司的最新新闻和分析师评级的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧